Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Evaluating Outcomes in Parkinson’s Disease Patients Following COVID-19 Interventions
Movement Disorders
S16 - Movement Disorders: PD Biomarkers and Clinical Trials (4:42 PM-4:54 PM)
007

Several studies have demonstrated an association between certain lifestyle behaviors, including exercise and social interaction, and positive PD outcomes. This study investigated specific PD patient outcome changes following both the disruption of many of those behaviors and the introduction of tele-medicine as the mainstay of outpatient visits. 

COVID-19 pandemic public health interventions upended many aspects of daily life. However, the effects on outcomes in Parkinson’s Disease (PD) patients remained unclear. This study was conducted to determine the impact those interventions had on the mood, movement, and quality of life (QOL) of PD patients. 

Comprehensive clinical assessments were conducted for 150 PD patients both before and after the onset of COVID-19 public health interventions. Through a retrospective chart review, quantitative disease markers and qualitative lifestyle changes were recorded and analyzed to determine changes in disease outcomes and QOL measures between the two subsequent visits.  These changes were also differentiated by visit type: in-person versus video versus telephone call. 

The paired analysis showed an increase in Hoehn and Yahr scale in the post-COVID patient visit in comparison to the pre-COVID visit from 1.86 to 2.02 (n = 122, p = 0.006.) Several non-movement PD symptoms worsened in the subsequent visits, including activities of daily living status, exercise frequency, and sleep disturbance frequency. Overall movement symptoms did not worsen, including bradykinesia, rigidity, resting tremor, gait abnormality, and falls, and patients did not have greater Levodopa needs. Outcome changes differentiated by visit type is pending.

The implementation of COVID-19 public health interventions was associated with worsening sleep habits and exercise frequency, as well as greater dependency in daily living among patients with PD. While QOL measures and non-movement PD symptoms worsened, no association was demonstrated between the pandemic interventions and worsening movement symptoms or greater levodopa needs.

Authors/Disclosures
Ari Vandersluis, DO (Loyola University Medical Center)
PRESENTER
Mr. Vandersluis has nothing to disclose.
Shnehal Patel, MD Dr. Patel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Adamas. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurocrine.
John Elliott No disclosure on file